CHARTERBioanalytics
Research Index

Real trials. Public data. No editorializing.

Charter does not publish marketing posts or opinion pieces. This index links to active, recruiting clinical trials on the compounds we test — sourced directly from ClinicalTrials.gov, the U.S. National Library of Medicine's registry of FDA-regulated trials worldwide.

Trials below are sponsor-registered and verified through the NIH/NLM registry. Charter is not affiliated with any sponsor listed and does not endorse or recommend participation. Trial entries are educational reference only. Click through to ClinicalTrials.gov for full eligibility criteria, protocols, locations, and contact information.

GLP-1 monotherapy: Semaglutide

NCT06184633 · Phase 4 · RECRUITING · n=280

Weight Control in Atrial Fibrillation (DUTCH-AF)

Sponsor: Rijnstate Hospital
Indication: Atrial Fibrillation + Obesity

View on ClinicalTrials.gov →
NCT07239570 · Phase 4 · RECRUITING · n=125

Biomarker-Targeted Treatment for Chronic Kidney Disease

Sponsor: Peter Rossing / Steno Diabetes Center
Indication: CKD

View on ClinicalTrials.gov →
NCT07171723 · Phase 1/2 · RECRUITING · n=24

Antagonizing Ghrelin Receptor with LEAP2 in Obesity on Semaglutide

Sponsor: University Hospital Gentofte (Copenhagen)
Indication: Obesity

View on ClinicalTrials.gov →

Dual-incretin agonist: Tirzepatide (GIP/GLP-1)

NCT06439277 · Phase 3 · RECRUITING · n=300

SURMOUNT-ADOLESCENTS-2: Tirzepatide Once-Weekly for Adolescent Obesity

Sponsor: Eli Lilly and Company
Indication: Adolescent Obesity

View on ClinicalTrials.gov →
NCT06721507 · Phase 4 · RECRUITING · n=50

Preoperative Tirzepatide for Bariatric Surgery

Sponsor: University of Kentucky
Indication: Bariatric Pre-op

View on ClinicalTrials.gov →
NCT06774079 · Phase 4 · RECRUITING · n=24

Tirzepatide + Mediterranean Diet in Crohn's Disease

Sponsor: University of Miami
Indication: Crohn's Disease

View on ClinicalTrials.gov →

Triple agonist: Retatrutide (GIP/GLP-1/Glucagon)

NCT06982859 · Phase 1 · RECRUITING · n=95

Effect of Retatrutide on α- and β-Cell Function in T2DM

Sponsor: Eli Lilly and Company
Indication: Type 2 Diabetes

View on ClinicalTrials.gov →

GHRH analog: Tesamorelin

NCT07481734 · Phase 2 · RECRUITING · n=120

Tesamorelin for Hepatic Steatosis in MASLD

Sponsor: Hudson Biotech
Indication: MASLD / NASH

View on ClinicalTrials.gov →

Amylin analog: Cagrilintide & CagriSema

NCT07527195 · Phase 1 · RECRUITING · n=100

CagriSema Effect on Skeletal Muscle Insulin Sensitivity, Composition, and Function

Sponsor: Novo Nordisk A/S
Indication: Obesity

View on ClinicalTrials.gov →
NCT07557953 · Phase 1 · RECRUITING · n=120

Cagrilintide Effect on Energy Intake and Appetite

Sponsor: Novo Nordisk A/S
Indication: Overweight / Obesity

View on ClinicalTrials.gov →
About this index. Listed trials are recruiting or actively enrolling as of the most recent ClinicalTrials.gov sync. Charter sources this list from the live NIH/NLM registry; status, enrollment, and contact details on ClinicalTrials.gov supersede anything shown here. For questions about peptide analytical testing, see Services; for questions about a specific trial, contact the sponsor through the linked registry page.